Comparative overview of innovation and patent filings in Radiopharmacy

Abstract

Objective To expose the current situation of the Brazilian Nuclear Medicine in relation to innovation, taking into account the Intellectual Property protection and the particularities of this field.Methods The number and the origin of patents filings from Brazil, United States and European Patent Convention countries were retrospectively compared in a 20-year period.Results The number of accumulated patents filings of conventional pharmaceuticals was ten times higher compared to the radiopharmaceuticals in the three regions studied.Conclusion The largest number of Brazilian patents filings corresponded to the international patent applications, which is related to the country development conditions, as well as to the difficulties in the process of patent filing.

Oldie but Goodie: Is Technetium-99m Still a Treasure Trove of Innovation for Medicine? A Patents Analysis (2000–2022)

“…Major drawbacks on patent counts have also been described. For instance, many patented inventions are not followed by an industrial application or market introduction, while others are not patentable or hardly highlighted because of different regulations across the countries . However, besides these significant limitations, the patent count is still considered a valuable and simple measure for innovation, correlating the number of patents as direct R&D output.…”